Download PDF
Thromb Haemost 2019; 119(01): 014-038
DOI: 10.1055/s-0038-1675816
Review Article
Georg Thieme Verlag KG Stuttgart · New York

The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations

Raffaele De Caterina   *
1   Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University of Chieti–Pescara, Pescara, Italy
2   University Cardiology Division, University of Pisa, Pisa University Hospital, Pisa, Italy
,
Walter Ageno
3   Department of Medicine and Surgery, University of Insubria, Varese, Italy
,
Giancarlo Agnelli
4   Department of Vascular Emergency Medicine–Stroke Unit, University of Perugia, Perugia, Italy
,
Noel C. Chan
5   Thrombosis and Atherosclerosis Research Institute, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Hans-Christoph Diener
6   Department of Neurology, Essen University Hospital, Essen, Germany
,
Elaine Hylek
7   Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston University, Boston, Massachusetts, United States
,
Gary E. Raskob
8   College of Public Health, University of Oklahoma Health Sciences Center, University of Oklahoma, Oklahoma City, Oklahoma, United States
,
Deborah M. Siegal
9   Population Health Research Institute, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Freek W. A. Verheugt
10   Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands
,
Gregory Y. H. Lip   *
11   Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
12   Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
,
Jeffrey I. Weitz   *
5   Thrombosis and Atherosclerosis Research Institute, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

09 May 2018

06 October 2018

Publication Date:
31 December 2018 (online)

Also available at
   Permissions and Reprints

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban and rivaroxaban, which inhibit factor Xa. In large clinical trials comparing the NOACs with the vitamin K antagonist (VKA) warfarin, dabigatran, apixaban, rivaroxaban and edoxaban were at least as effective for stroke prevention in atrial fibrillation and for treatment of venous thromboembolism, but were associated with less intracranial bleeding. In addition, the NOACs are more convenient to administer than VKAs because they can be given in fixed doses without routine coagulation monitoring. Consequently, the NOACs are now replacing VKAs for these indications, and their use is increasing. Although, as a class, the NOACs have a favourable benefit–risk profile compared with VKAs, choosing among them is complicated because they have not been compared in head-to-head trials. Therefore, selection depends on the results of the individual trials, renal function, the potential for drug–drug interactions and preference for once- or twice-daily dosing. In addition, several ‘special situations’ were not adequately studied in the dedicated clinical trials. For these situations, knowledge of the unique pharmacological features of the various NOACs and judicious cross-trial comparison can help inform prescription choices. The purpose of this position article is therefore to help clinicians choose the right anticoagulant for the right patient at the right dose by reviewing a variety of special situations not widely studied in clinical trials.

Keywords

oral anticoagulants - non-vitamin K antagonist oral anticoagulants - NOACs - special situations

* Document Coordinators and joint Senior Authors: Raffaele De Caterina, Gregory Y. H. Lip and Jeffrey I. Weitz.


 

  • References

  • 1 Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost 2017; 117 (07) 1230-1239
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Schulman S, Ageno W, Konstantinides SV. Venous thromboembolism: past, present and future. Thromb Haemost 2017; 117 (07) 1219-1229
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Steffel J, Verhamme P, Potpara TS. , et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
    CrossrefPubMedGoogle Scholar
  • 4 De Caterina R, Husted S, Wallentin L. , et al; Coordinating Committee. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012; 59 (16) 1413-1425
    CrossrefPubMedGoogle Scholar
  • 5 De Caterina R, Husted S, Wallentin L. , et al; European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. General mechanisms of coagulation and targets of anticoagulants (Section I). Thromb Haemost 2013; 109 (04) 569-579
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 De Caterina R, Husted S, Wallentin L. , et al; European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109 (05) 769-786
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 De Caterina R, Husted S, Wallentin L. , et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110 (06) 1087-1107
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 De Caterina R, Husted S, Wallentin L. , et al. Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2016; 115 (04) 685-711
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Connolly SJ, Ezekowitz MD, Yusuf S. , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    CrossrefPubMedGoogle Scholar
  • 10 Patel MR, Mahaffey KW, Garg J. , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    CrossrefPubMedGoogle Scholar
  • 11 Granger CB, Alexander JH, McMurray JJ. , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 12 Giugliano RP, Ruff CT, Braunwald E. , et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    CrossrefPubMedGoogle Scholar
  • 13 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 14 Schulman S, Kearon C, Kakkar AK. , et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (08) 709-718
    CrossrefPubMedGoogle Scholar
  • 15 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 16 Büller HR, Prins MH, Lensin AW. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 17 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 18 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 19 Weitz JI, Lensing AWA, Prins MH. , et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
    CrossrefPubMedGoogle Scholar
  • 20 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 21 Eriksson BI, Borris LC, Friedman RJ. , et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358 (26) 2765-2775
    CrossrefPubMedGoogle Scholar
  • 22 Lassen MR, Ageno W, Borris LC. , et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358 (26) 2776-2786
    CrossrefPubMedGoogle Scholar
  • 23 Turpie AG, Lassen MR, Davidson BL. , et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373 (9676): 1673-1680
    CrossrefPubMedGoogle Scholar
  • 24 Eriksson BI, Dahl OE, Rosencher N. , et al; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370 (9591): 949-956
    CrossrefPubMedGoogle Scholar
  • 25 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361 (06) 594-604
    CrossrefPubMedGoogle Scholar
  • 26 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. ; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375 (9717): 807-815
    CrossrefPubMedGoogle Scholar
  • 27 Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. ; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363 (26) 2487-2498
    CrossrefPubMedGoogle Scholar
  • 28 Cohen AT, Harrington RA, Goldhaber SZ. , et al; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016; 375 (06) 534-544
    CrossrefPubMedGoogle Scholar
  • 29 Boehringer-Ingelheim Pharmaceuticals G. Pradaxa® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/medicine/24839 ; updated on March 8, 2016 . Accessed September 9, 2018
    PubMedGoogle Scholar
  • 30 Boehringer-Ingelheim Pharmaceuticals G. Pradaxa® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/medicine/24839 . Accessed September 9, 2018
    PubMedGoogle Scholar
  • 31 Bayer Pharma AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf . Accessed February 14, 2018
    PubMedGoogle Scholar
  • 32 Bristol-Myers Squibb-Pfizer. Eliquis® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/history/27220 ; last updated on January 22, 2016. Accessed April 20, 2018
    PubMedGoogle Scholar
  • 33 Sankyo D. Lixiana Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/medicine/30506 ; last updated on August 25, 2016 . Accessed April 20, 2018
    PubMedGoogle Scholar
  • 34 Portola Pharmaceuticals I. Bevyxxa® Summary of Product Characteristics. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf . Accessed October 28, 2018
    PubMedGoogle Scholar
  • 35 Eikelboom JW, Connolly SJ, Brueckmann M. , et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369 (13) 1206-1214
    CrossrefPubMedGoogle Scholar
  • 36 Zühlke L, Engel ME, Karthikeyan G. , et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J 2015; 36 (18) 1115-1122
    CrossrefPubMedGoogle Scholar
  • 37 De Caterina R, John Camm A. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. Europace 2016; 18 (01) 6-11
    CrossrefPubMedGoogle Scholar
  • 38 Cozzolino M, Brandenburg V. Warfarin: to use or not to use in chronic kidney disease patients?. J Nephrol 2010; 23 (06) 648-652
    PubMedGoogle Scholar
  • 39 Brodsky SV, Nadasdy T, Rovin BH. , et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80 (02) 181-189
    CrossrefPubMedGoogle Scholar
  • 40 Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60 (08) 646-649
    CrossrefPubMedGoogle Scholar
  • 41 Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 2017; 151 (01) 127-138
    CrossrefPubMedGoogle Scholar
  • 42 Kate M, Szkotak A, Witt A, Shuaib A, Butcher K. Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. J Stroke Cerebrovasc Dis 2014; 23 (06) 1351-1355
    CrossrefPubMedGoogle Scholar
  • 43 Reilly PA, Lehr T, Haertter S. , et al; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63 (04) 321-328
    CrossrefPubMedGoogle Scholar
  • 44 Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50 (10) 675-686
    CrossrefPubMedGoogle Scholar
  • 45 Ruff CT, Giugliano RP, Braunwald E. , et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; 385 (9984): 2288-2295
    CrossrefPubMedGoogle Scholar
  • 46 Pernod G, Albaladejo P, Godier A. , et al; Working Group on Perioperative Haemostasis. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis 2013; 106 (6-7): 382-393
    CrossrefPubMedGoogle Scholar
  • 47 Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. ; Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (03) 623-627
    CrossrefPubMedGoogle Scholar
  • 48 Ruff CT, Giugliano RP, Braunwald E. , et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921): 955-962
    CrossrefPubMedGoogle Scholar
  • 49 Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 2015; 13 (11) 2012-2020
    CrossrefPubMedGoogle Scholar
  • 50 Glund S, Stangier J, Schmohl M. , et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015; 386 (9994): 680-690
    CrossrefPubMedGoogle Scholar
  • 51 Pollack Jr CV, Reilly PA, Eikelboom J. , et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (06) 511-520
    CrossrefPubMedGoogle Scholar
  • 52 Pollack Jr CV, Reilly PA, van Ryn J. , et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 2017; 377 (05) 431-441
    CrossrefPubMedGoogle Scholar
  • 53 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124 (14) 1573-1579
    CrossrefPubMedGoogle Scholar
  • 54 Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108 (02) 217-224
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S. The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 2013; 35 (02) 222-224
    CrossrefPubMedGoogle Scholar
  • 56 Solbeck S, Meyer MA, Johansson PI. , et al. Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography. Int J Cardiol 2014; 176 (03) 794-799
    CrossrefPubMedGoogle Scholar
  • 57 Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 2014; 111 (05) 989-995
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Arellano-Rodrigo E, Lopez-Vilchez I, Galan AM. , et al. Coagulation factor concentrates fail to restore alterations in fibrin formation caused by rivaroxaban or dabigatran in studies with flowing blood from treated healthy volunteers. Transfus Med Rev 2015; 29 (04) 242-249
    CrossrefPubMedGoogle Scholar
  • 59 Khadzhynov D, Wagner F, Formella S. , et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013; 109 (04) 596-605
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M. Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. J Thromb Haemost 2015; 13 (10) 1790-1798
    CrossrefPubMedGoogle Scholar
  • 61 Lu G, DeGuzman FR, Hollenbach SJ. , et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19 (04) 446-451
    CrossrefPubMedGoogle Scholar
  • 62 Siegal DM, Curnutte JT, Connolly SJ. , et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373 (25) 2413-2424
    CrossrefPubMedGoogle Scholar
  • 63 Connolly SJ, Milling Jr TJ, Eikelboom JW. , et al; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375 (12) 1131-1141
    CrossrefPubMedGoogle Scholar
  • 64 Sullivan Jr DW, Gad SC, Laulicht B, Bakhru S, Steiner S. Nonclinical safety assessment of PER977: a small molecule reversal agent for new oral anticoagulants and heparins. Int J Toxicol 2015; 34 (04) 308-317
    CrossrefPubMedGoogle Scholar
  • 65 Ansell JE, Bakhru SH, Laulicht BE. , et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014; 371 (22) 2141-2142
    CrossrefPubMedGoogle Scholar
  • 66 Levi M, Moore KT, Castillejos CF. , et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014; 12 (09) 1428-1436
    CrossrefPubMedGoogle Scholar
  • 67 Zahir H, Brown KS, Vandell AG. , et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131 (01) 82-90
    CrossrefPubMedGoogle Scholar
  • 68 Brown KS, Wickremasingha P, Parasrampuria DA. , et al. The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban. Thromb Res 2015; 136 (04) 825-831
    CrossrefPubMedGoogle Scholar
  • 69 Cheung YW, Barco S, Hutten BA, Meijers JC, Middeldorp S, Coppens M. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J Thromb Haemost 2015; 13 (10) 1799-1805
    CrossrefPubMedGoogle Scholar
  • 70 Barco S, Whitney Cheung Y, Coppens M, Hutten BA, Meijers JC, Middeldorp S. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. Br J Haematol 2016; 172 (02) 255-261
    CrossrefPubMedGoogle Scholar
  • 71 Nagalla S, Thomson L, Oppong Y, Bachman B, Chervoneva I, Kraft WK. Reversibility of apixaban anticoagulation with a four-factor prothrombin complex concentrate in healthy volunteers. Clin Transl Sci 2016; 9 (03) 176-180
    CrossrefPubMedGoogle Scholar
  • 72 Gerner ST, Kuramatsu JB, Sembill JA. , et al; RETRACE II (German-Wide Multicenter Analysis of Oral Anticoagulation-Associated Intracerebral Hemorrhage II) Investigators. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol 2018; 83 (01) 186-196
    CrossrefPubMedGoogle Scholar
  • 73 Majeed A, Ågren A, Holmström M. , et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017; 130 (15) 1706-1712
    CrossrefPubMedGoogle Scholar
  • 74 Schulman S, Ritchie B, Nahirniak S. , et al; Study investigators. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: a prospective cohort study. Thromb Res 2017; 152: 44-48
    CrossrefPubMedGoogle Scholar
  • 75 Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009; 373 (9658): 155-166
    CrossrefPubMedGoogle Scholar
  • 76 Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006; 37 (09) 2294-2300
    CrossrefPubMedGoogle Scholar
  • 77 Hijazi Z, Lindbäck J, Alexander JH. , et al; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016; 37 (20) 1582-1590
    CrossrefPubMedGoogle Scholar
  • 78 Hijazi Z, Oldgren J, Lindbäck J. , et al; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387 (10035): 2302-2311
    CrossrefPubMedGoogle Scholar
  • 79 Hijazi Z, Oldgren J, Lindbäck J. , et al; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J 2018; 39 (06) 477-485
    CrossrefPubMedGoogle Scholar
  • 80 Kirchhof P, Benussi S, Kotecha D. , et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). Eur Heart J 2016; 37: 2893-2962
    CrossrefPubMedGoogle Scholar
  • 81 Roldan V, Rivera-Caravaca JM, Shantsila A. , et al. Enhancing the ‘real world’ prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers. Ann Med 2018; 50 (01) 26-34
    CrossrefPubMedGoogle Scholar
  • 82 García-Fernández A, Roldán V, Rivera-Caravaca JM. , et al. Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?. Sci Rep 2017; 7: 41565
    CrossrefPubMedGoogle Scholar
  • 83 Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA. , et al. Long-term stroke risk prediction in patients with atrial fibrillation: comparison of the ABC-stroke and CHA2DS2-VASc scores. J Am Heart Assoc 2017; 6 (07) 6
    CrossrefPubMedGoogle Scholar
  • 84 Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, Roldán V, Lip GYH, Marín F. Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial. Thromb Haemost 2017; 117 (12) 2261-2266
    Article in Thieme ConnectPubMedGoogle Scholar
  • 85 Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14 (11) 627-628
    CrossrefPubMedGoogle Scholar
  • 86 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 87 Kyrle PA, Eichinger S. Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemost 2012; 108 (06) 1061-1064
    Article in Thieme ConnectPubMedGoogle Scholar
  • 88 Prandoni P, Vedovetto V, Ciammaichella M. , et al; Morgagni Investigators. Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis. Thromb Res 2017; 154: 35-41
    CrossrefPubMedGoogle Scholar
  • 89 Grifoni S, Vanni S, Magazzini S. , et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med 2006; 166 (19) 2151-2156
    CrossrefPubMedGoogle Scholar
  • 90 Rodger MA, Kahn SR, Wells PS. , et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179 (05) 417-426
    CrossrefPubMedGoogle Scholar
  • 91 Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121 (14) 1630-1636
    CrossrefPubMedGoogle Scholar
  • 92 Tosetto A, Iorio A, Marcucci M. , et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10 (06) 1019-1025
    CrossrefPubMedGoogle Scholar
  • 93 Poli D, Palareti G. Assessing recurrence risk following acute venous thromboembolism: use of algorithms. Curr Opin Pulm Med 2013; 19 (05) 407-412
    CrossrefPubMedGoogle Scholar
  • 94 Franco Moreno AI, García Navarro MJ, Ortiz Sánchez J. , et al. A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES). Eur J Intern Med 2016; 29: 59-64
    CrossrefPubMedGoogle Scholar
  • 95 Rodger MA, Le Gal G, Anderson DR. , et al; REVERSE II Study Investigators. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ 2017; 356: j1065
    CrossrefPubMedGoogle Scholar
  • 96 Tosetto A, Testa S, Martinelli I. , et al. External validation of the DASH prediction rule: a retrospective cohort study. J Thromb Haemost 2017; 15 (10) 1963-1970
    CrossrefPubMedGoogle Scholar
  • 97 Franco Moreno AI, García Navarro MJ, Ortiz Sánchez J, Ruiz Giardín JM. Predicting recurrence after a first unprovoked venous thromboembolism: retrospective validation of the DAMOVES score. Eur J Intern Med 2017; 41: e15-e16
    CrossrefPubMedGoogle Scholar
  • 98 Kearon C, Parpia S, Spencer FA. , et al. D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment. Thromb Res 2016; 146: 119-125
    CrossrefPubMedGoogle Scholar
  • 99 Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G. ; SSC of the ISTH. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost 2012; 10 (04) 698-702
    CrossrefPubMedGoogle Scholar
  • 100 Undas A, Zawilska K, Ciesla-Dul M. , et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114 (19) 4272-4278
    CrossrefPubMedGoogle Scholar
  • 101 Dzikowska-Diduch O, Domienik-Karłowicz J, Górska E, Demkow U, Pruszczyk P, Kostrubiec M. E-selectin and sICAM-1, biomarkers of endothelial function, predict recurrence of venous thromboembolism. Thromb Res 2017; 157: 173-180
    CrossrefPubMedGoogle Scholar
  • 102 Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014; 64 (11) 1128-1139
    CrossrefPubMedGoogle Scholar
  • 103 Verheugt FW, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet 2015; 386 (9990): 303-310
    CrossrefPubMedGoogle Scholar
  • 104 Cappato R, Ezekowitz MD, Klein AL. , et al; X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; 35 (47) 3346-3355
    CrossrefPubMedGoogle Scholar
  • 105 Goette A, Merino JL, Ezekowitz MD. , et al; ENSURE-AF investigators. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016; 388 (10055): 1995-2003
    CrossrefPubMedGoogle Scholar
  • 106 Ezekowitz MD, Pollack Jr CV, Halperin JL. , et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J 2018; 39 (32) 2959-2971
    CrossrefPubMedGoogle Scholar
  • 107 Renda G, Ricci F, De Caterina R. Non-vitamin K antagonist oral anticoagulants for cardioversion in atrial fibrillation: an updated meta-analysis. Am J Med 2017; 130 (04) 457-461
    CrossrefPubMedGoogle Scholar
  • 108 Cappato R, Marchlinski FE, Hohnloser SH. , et al; VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015; 36 (28) 1805-1811
    CrossrefPubMedGoogle Scholar
  • 109 Calkins H, Willems S, Gerstenfeld EP. , et al; RE-CIRCUIT Investigators. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 2017; 376 (17) 1627-1636
    CrossrefPubMedGoogle Scholar
  • 110 Gibson CM, Mehran R, Bode C. , et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375 (25) 2423-2434
    CrossrefPubMedGoogle Scholar
  • 111 Cannon CP, Bhatt DL, Oldgren J. , et al; RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377 (16) 1513-1524
    CrossrefPubMedGoogle Scholar
  • 112 Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 2013; 52 (02) 69-82
    CrossrefPubMedGoogle Scholar
  • 113 Barba R, Marco J, Martín-Alvarez H. , et al; RIETE investigators. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 2005; 3 (05) 856-862
    CrossrefPubMedGoogle Scholar
  • 114 De Caterina R, Lip GYH. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol 2017; 106 (08) 565-572
    CrossrefPubMedGoogle Scholar
  • 115 Vanassche T, Vandenbriele C, Peerlinck K, Verhamme P. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. Expert Opin Pharmacother 2015; 16 (05) 645-658
    CrossrefPubMedGoogle Scholar
  • 116 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
    CrossrefPubMedGoogle Scholar
  • 117 Whiteley WN, Adams Jr HP, Bath PM. , et al. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurol 2013; 12 (06) 539-545
    CrossrefPubMedGoogle Scholar
  • 118 Arihiro S, Todo K, Koga M. , et al; SAMURAI Study Investigators. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: the SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke 2016; 11 (05) 565-574
    CrossrefPubMedGoogle Scholar
  • 119 Paciaroni M, Agnelli G, Ageno W, Caso V. Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. Thromb Haemost 2016; 116 (03) 410-416
    Article in Thieme ConnectPubMedGoogle Scholar
  • 120 Paciaroni M, Agnelli G, Caso V. , et al. Prediction of early recurrent thromboembolic event and major bleeding in patients with acute stroke and atrial fibrillation by a risk stratification schema: the ALESSA score study. Stroke 2017; 48 (03) 726-732
    CrossrefPubMedGoogle Scholar
  • 121 Kirchhof P, Benussi S, Kotecha D. , et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
    CrossrefPubMedGoogle Scholar
  • 122 Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 2017; 12 (06) 589-596
    CrossrefPubMedGoogle Scholar
  • 123 Tepper PG, Liu X, Hamilton M. , et al. Ischemic stroke in nonvalvular atrial fibrillation at warfarin initiation: assessment via a large insurance database. Stroke 2017; 48 (06) 1487-1494
    CrossrefPubMedGoogle Scholar
  • 124 Diener HC, Granger CB, Patel MR. Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?. Eur Heart J 2014; 35 (28) 1834-1835
    CrossrefPubMedGoogle Scholar
  • 125 Johnson&Johnson. Available at: https://www.jnj.com/media-center/press-releases/navigate-esus-study-stopped-early-due-to-comparable-efficacy-in-treatment-arms . Accessed May 1, 2018
    PubMed
  • 126 Israel C, Kitsiou A, Kalyani M. , et al. Detection of atrial fibrillation in patients with embolic stroke of undetermined source by prolonged monitoring with implantable loop recorders. Thromb Haemost 2017; 117 (10) 1962-1969
    Article in Thieme ConnectPubMedGoogle Scholar
  • 127 Wachter R, Freedman B. The role of atrial fibrillation in patients with an embolic stroke of unknown source (ESUS). Thromb Haemost 2017; 117 (10) 1833-1835
    Article in Thieme ConnectPubMedGoogle Scholar
  • 128 Kuramatsu JB, Gerner ST, Schellinger PD. , et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313 (08) 824-836
    CrossrefPubMedGoogle Scholar
  • 129 Murthy SB, Gupta A, Merkler AE. , et al. Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis. Stroke 2017; 48 (06) 1594-1600
    CrossrefPubMedGoogle Scholar
  • 130 Holmes Jr DR, Doshi SK, Kar S. , et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 2015; 65 (24) 2614-2623
    CrossrefPubMedGoogle Scholar
  • 131 Connolly SJ, Eikelboom J, Joyner C. , et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (09) 806-817
    CrossrefPubMedGoogle Scholar
  • 132 Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary embolism and atrial fibrillation: two sides of the same coin? A systematic review. Semin Thromb Hemost 2017; 43 (08) 849-863
    Article in Thieme ConnectPubMedGoogle Scholar
  • 133 Weitz JI, Jaffer IH, Fredenburgh JC. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. F1000 Res 2017; 6: 985
    CrossrefPubMedGoogle Scholar
  • 134 Agewall S, Camm J. New ESC/EACTS Guidelines for the management of atrial fibrillation. Eur Heart J Cardiovasc Pharmacother 2017; 3 (02) 71-72
    PubMedGoogle Scholar
  • 135 Raskob GE, van Es N, Verhamme P. , et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedGoogle Scholar
  • 136 Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist 2014; 19 (01) 82-93
    CrossrefPubMedGoogle Scholar
  • 137 Raschi E, Bianchin M, Ageno W, De Ponti R, De Ponti F. Risk-benefit profile of direct-acting oral anticoagulants in established therapeutic indications: an overview of systematic reviews and observational studies. Drug Saf 2016; 39 (12) 1175-1187
    CrossrefPubMedGoogle Scholar
  • 138 Levine MN, Gu C, Liebman HA. , et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012; 10 (05) 807-814
    CrossrefPubMedGoogle Scholar
  • 139 Khorana AA, Vadhan-Raj S, Kuderer NM. , et al. Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI Trial. Rationale and design of the CASSINI trial. Thromb Haemost 2017; 117 (11) 2135-2145
    Article in Thieme ConnectPubMedGoogle Scholar
  • 140 Prins MH, Lensing AW, Brighton TA. , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (01) e37-e46
    PubMedGoogle Scholar
  • 141 Agnelli G, Buller HR, Cohen A. , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 2015; 13 (12) 2187-2191
    CrossrefPubMedGoogle Scholar
  • 142 Schulman S, Goldhaber SZ, Kearon C. , et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114 (01) 150-157
    Article in Thieme ConnectPubMedGoogle Scholar
  • 143 Raskob GE, van Es N, Segers A. , et al; Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 2016; 3 (08) e379-e387
    PubMedGoogle Scholar
  • 144 Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147 (02) 475-483
    CrossrefPubMedGoogle Scholar
  • 145 Di Minno MND, Ageno W, Lupoli R. , et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials. Eur Respir J 2017; 50 (03) 50
    CrossrefPubMedGoogle Scholar
  • 146 van Es N, Di Nisio M, Bleker SM. , et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 2015; 114 (06) 1268-1276
    Article in Thieme ConnectPubMedGoogle Scholar
  • 147 Bott-Kitslaar DM, Saadiq RA, McBane RD. , et al. Efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy: a single-center registry. Am J Med 2016; 129 (06) 615-619
    CrossrefPubMedGoogle Scholar
  • 148 Melloni C, Dunning A, Granger CB. , et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med 2017; 130 (12) 1440-1448.e1
    CrossrefPubMedGoogle Scholar
  • 149 Laube ES, Yu A, Gupta D. , et al. Rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation and active cancer. Am J Cardiol 2017; 120 (02) 213-217
    CrossrefPubMedGoogle Scholar
  • 150 Ording AG, Horváth-Puhó E, Adelborg K, Pedersen L, Prandoni P, Sørensen HT. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med 2017; 6 (06) 1165-1172
    CrossrefPubMedGoogle Scholar
  • 151 Fanola C, Ruff C, Murphy S. , et al. Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 2018; 2018: e008987
    PubMedGoogle Scholar
  • 152 Spyropoulos AC, Raskob GE. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost 2017; 117 (09) 1662-1670
    Article in Thieme ConnectPubMedGoogle Scholar
  • 153 Kahn SR, Lim W, Dunn AS. , et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e195S-e226S
    CrossrefPubMedGoogle Scholar
  • 154 Nicolaides AN, Fareed J, Kakkar AK. , et al. Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol 2013; 32 (02) 111-260
    PubMedGoogle Scholar
  • 155 Goldhaber SZ, Leizorovicz A, Kakkar AK. , et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365 (23) 2167-2177
    CrossrefPubMedGoogle Scholar
  • 156 Cohen AT, Spiro TE, Büller HR. , et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368 (06) 513-523
    CrossrefPubMedGoogle Scholar
  • 157 Gibson C, Spyropoulos A, Cohen A. , et al. The IMPROVEDD VTE risk score: incorporation of D-dimer into the IMPROVE Score to improve venous thromboembolism risk stratification. TH Open 2017; 1: e56-e65
    Article in Thieme ConnectPubMedGoogle Scholar
  • 158 Gibson CM, Chi G, Halaby R. , et al; APEX Investigators. Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation 2017; 135 (07) 648-655
    CrossrefPubMedGoogle Scholar
  • 159 Spyropoulos AC, Ageno W, Albers GW. , et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018; 379 (12) 1118-1127
    CrossrefPubMedGoogle Scholar
  • 160 Weitz JI, Harenberg J. New developments in anticoagulants: past, present and future. Thromb Haemost 2017; 117 (07) 1283-1288
    Article in Thieme ConnectPubMedGoogle Scholar
  • 161 Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107 (05) 838-847
    Article in Thieme ConnectPubMedGoogle Scholar
  • 162 Heidbuchel H, Verhamme P, Alings M. , et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17 (10) 1467-1507
    CrossrefPubMedGoogle Scholar
  • 163 European Medicinal Agency. Apixaban, Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf . Accessed November 29, 2017
    PubMed
  • 164 Tritschler T, Méan M, Limacher A, Rodondi N, Aujesky D. Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model. Blood 2015; 126 (16) 1949-1951
    CrossrefPubMedGoogle Scholar
  • 165 Raskob GE, Spyropoulos AC, Zrubek J. , et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost 2016; 115 (06) 1240-1248
    Article in Thieme ConnectPubMedGoogle Scholar
  • 166 Ezekowitz M. Apixaban versus heparin/vitamin K antagonist in anticoagulation-naïve patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Presented at the European Congress of Cardiology; 2017 , Barcelona. Available at: https://www.escardio.org/The-ESC/Press-Office/Press-releases/apixaban-lowers-stroke-risk-in-atrial-fibrillation-patients-undergoing-cardioversion . Accessed February 14, 2018
    PubMedGoogle Scholar